{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:01:00Z","timestamp":1792036860265,"version":"4.4.0"},"reference-count":60,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>B\u2010cell maturation antigen (BCMA)\u2010targeting immunotherapies (e.g., chimeric antigen receptor T cells (CAR\u2010T) and bispecific antibodies (BsAbs)) have achieved remarkable clinical responses in patients with relapsed and\/or refractory multiple myeloma (RRMM). Their use is accompanied by exaggerated immune responses related to T\u2010cell activation and cytokine elevations leading to cytokine release syndrome (CRS) in some patients, which can be potentially life\u2010threatening. However, systematic evaluation of the risk of CRS with BCMA\u2010targeting BsAb and CAR\u2010T therapies, and comparisons across different routes of BsAb administration (intravenous (i.v.) vs. subcutaneous (s.c.)) have not previously been conducted. This study utilized a meta\u2010analysis approach to compare the CRS profile in BCMA\u2010targeting CAR\u2010T vs. BsAb immunotherapies administered either i.v. or s.c. in patients with RRMM. A total of 36 studies including 1,560 patients with RRMM treated with BCMA\u2010targeting CAR\u2010T and BsAb therapies were included in the analysis. The current analysis suggests that compared with BsAbs, CAR\u2010T therapies were associated with higher CRS incidences (88% vs. 59%), higher rates of grade \u2265\u20093 CRS (7% vs. 2%), longer CRS duration (5 vs. 2\u2009days), and more prevalent tocilizumab use (44% vs. 25%). The proportion of CRS grade \u2265\u20093 may also be lower (0% vs. 4%) for BsAb therapies administered via the s.c. (3 studies, <jats:italic>n<\/jats:italic>\u2009=\u2009311) vs. i.v. (5 studies, <jats:italic>n<\/jats:italic>\u2009=\u2009338) route. This meta\u2010analysis suggests that different types of BCMA\u2010targeting immunotherapies and administration routes could result in a range of CRS incidence and severity that should be considered while evaluating the benefit\u2013risk profiles of these therapies.<\/jats:p>","DOI":"10.1002\/cpt.3223","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T04:22:09Z","timestamp":1709958129000},"page":"1258-1268","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta\u2010Analysis"],"prefix":"10.1002","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1396-113X","authenticated-orcid":false,"given":"Pooneh","family":"Soltantabar","sequence":"first","affiliation":[{"name":"Oncology Research and Development Pfizer Inc  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Sharma","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc  San Diego California USA"},{"name":"Department of Pharmaceutical Sciences Washington State University  Spokane Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wang","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi\u2010Kei","family":"Lon","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akos","family":"Czibere","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hickmann","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9825-5890","authenticated-orcid":false,"given":"Mohamed","family":"Elmeliegy","sequence":"additional","affiliation":[{"name":"Oncology Research and Development Pfizer Inc  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17805"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184088"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0028"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01793-1"},{"key":"e_1_2_11_9_1","unstructured":"ELREXFIO<https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010elranatamab\u2010bcmm\u2010multiple\u2010myeloma#:~:text=On\u2009August\u200914%2C\u20092023%2C\u2009the four\u2009prior\u2009lines\u2009of\u2009therapy%2C>."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00474-4"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215190"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611366"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01892"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2181016"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01001-1"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13380"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.46811"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1970218"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002742"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45778-9"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2013-203104"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-022-02977-6"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00377-8"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00242-0"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0495-9"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163192"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34756"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159009"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00628-2"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-017-0074-5"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2728-5"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12662"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03237"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17527"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001463"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00547-6"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159381"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8033"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/1547691X.2020.1729902"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.013"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8006"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8011"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8013"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138831"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169971"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121805"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-144921"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134063"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846616.21003.5d"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:25:13Z","timestamp":1715577913000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/cpt.3223"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3223","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"2023-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}